<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934852</url>
  </required_header>
  <id_info>
    <org_study_id>20210615</org_study_id>
    <nct_id>NCT04934852</nct_id>
  </id_info>
  <brief_title>Biphasic Effects of Different Doses Ephedrine on Hemodynamics in Elderly Patients Under General Anesthesia</brief_title>
  <official_title>Biphasic Effects of Different Doses Ephedrine on Hemodynamics in Elderly Patients Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ephedrine is commonly clinically vasoactive drugs, which can constrict blood vessels and&#xD;
      increase blood pressure. Ephedrine can not only stimulate α receptors, but also β receptors,&#xD;
      that's to say, it can increase heart rate, stroke volume, and cardiac output, but it also can&#xD;
      decrease the level of systemic vascular resistance. This research aims to observe the&#xD;
      short-term vasodilator effect of diffierent doses of ephedrine used in elderly patients under&#xD;
      general anesthesia in clinical practice, and analyze the main reasons for this phenomenon and&#xD;
      take preventive actions to minimize the possibility of further lowering of blood pressure to&#xD;
      provide references for clinical rational use of drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of systemic vascular resistance</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of cardiac output</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of cardiac index</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of heart rate</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of heart rate cardiac circulation efficiency</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of maximum pressure gradient</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of mean arterial pressure</measure>
    <time_frame>during surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>The outcomes above should be measured at Immediately after the injection of the drug (T1), 30s after the injection (T2), 1 min after the injection(T3), 1 min30 s after the injection(T4), 2 min after the injection(T5), 2 min30s after the injection(T6), 3 min after the injection(T7), 3 min30s after the injection( T8), 4 min after the injection(T9), 4 min30s after the injection(T10), 5 min after the injection(T11), immediately after surgery (T12), 30 min in PACU (T13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of infusion volume,propofol and remifentanil</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of adverse events about the cardiovascular system</measure>
    <time_frame>from the beginning of the surgery to 30 minutes after being sent to the PACU</time_frame>
    <description>Yes or No</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>ephedrine (4mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ephedrine (8mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ephedrine (12mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <description>When elderly patients had hypotension (invasive blood pressure drops &gt;20% from the baseline value or &lt;100 mmHg, or MAP &lt;70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously</description>
    <arm_group_label>ephedrine (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <description>When elderly patients had hypotension (invasive blood pressure drops &gt;20% from the baseline value or &lt;100 mmHg, or MAP &lt;70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously</description>
    <arm_group_label>ephedrine (8mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <description>When elderly patients had hypotension (invasive blood pressure drops &gt;20% from the baseline value or &lt;100 mmHg, or MAP &lt;70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously</description>
    <arm_group_label>ephedrine (12mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages ranged from 65 to 80&#xD;
&#xD;
          -  ASA I~II&#xD;
&#xD;
          -  patients undergoing elective general anesthesia&#xD;
&#xD;
          -  BMI 18.5-30.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of patients&#xD;
&#xD;
          -  emergency surgery, neurological or mental disorders , Liver and kidney dysfunction&#xD;
&#xD;
          -  previous allergy to ephedrine and phenylephrine&#xD;
&#xD;
          -  heart disease history, such as pacemaker implantation, unstable angina, congestive&#xD;
             heart failure, Heart valve disease&#xD;
&#xD;
          -  nerve, digestive, endocrine system diseases, and affect intravascular Fluid volume or&#xD;
             balance diseases (such as inflammatory diseases or gastrointestinal obstructive&#xD;
             diseases)&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  malignant tumors&#xD;
&#xD;
          -  tachycardia (HR&gt;100)&#xD;
&#xD;
          -  bradycardia ( HR&lt;50)&#xD;
&#xD;
          -  intraoperative hypotension that is difficult to correct with ephedrine and&#xD;
             phenylephrine&#xD;
&#xD;
          -  use of other vasoactive drugs.&#xD;
&#xD;
          -  surgery time &lt;40 min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhuan Zhang, Professor</last_name>
    <phone>+8615062791355</phone>
    <email>zhangzhuancg@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University, Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuan Zhang, professor</last_name>
      <phone>+8615062791355</phone>
      <phone_ext>+8615062791355</phone_ext>
      <email>zhangzhuancg@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ephedrine</keyword>
  <keyword>Biphasic Effects</keyword>
  <keyword>Elderly</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

